Prognostic impact of immune-related adverse events with nivolumab or pembrolizumab monotherapy in patients with advanced gastric cancer: A multicenter retrospective analysis

被引：0
|
作者：
Motoo, I. [1 ]
Ando, T. [1 ]
Ueda, A. [2 ]
Ogawa, K. [3 ]
Kajiura, S. [1 ]
Hirano, K. [4 ]
Okumura, T. [4 ]
Tsukada, K. [5 ]
Hara, T. [6 ]
Suzuki, N. [7 ]
Nakada, N. [8 ]
Takatori, S. [9 ]
Horikawa, N. [10 ]
Fujii, T. [4 ]
Yasuda, I. [1 ]
机构：
[1] Univ Toyama, Dept Internal Med 3, Toyama, Japan
[2] Toyama Red Cross Hosp, Dept Med Oncol, Toyama, Japan
[3] Toyama Prefectural Cent Hosp, Dept Gastroenterol, Toyama, Japan
[4] Univ Toyama, Acad Assembly, Dept Surg & Sci, Fac Med, Toyama, Japan
[5] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[6] Koseiren Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan
[7] Joetsu Gen Hosp, Dept Gastroenterol, Joetsu, Japan
[8] Itoigawa Sogo Hosp, Dept Internal Med, Itoigawa, Japan
[9] Saiseikai Toyama Hosp, Dept Gastroenterol, Toyama, Japan
[10] Takaoka City Hosp, Dept Surg, Takaoka, Toyama, Japan
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-178
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [1] Prognostic impact of immune-related adverse events with nivolumab in patients with advanced gastric cancer: A multicenter retrospective analysis
    Ohya, Yuno
    Ando, Takayuki
    Ueda, Akira
    Ogawa, Kohei
    Motoo, Iori
    Kajiura, Shinya
    Tsukada, Kenichiro
    Hara, Takuo
    Suzuki, Nobuhiro
    Nakada, Naokatsu
    Takatori, Shunsuke
    Horikawa, Naoki
    Fujii, Tsutomu
    Yasuda, Ichiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis
    Ando, Takayuki
    Ueda, Akira
    Ogawa, Kohei
    Motoo, Iori
    Kajiura, Shinya
    Nakajima, Takahiko
    Hirano, Katsuhisa
    Okumura, Tomoyuki
    Tsukada, Kenichiro
    Hara, Takuo
    Suzuki, Nobuhiro
    Nakada, Naokatsu
    Horikawa, Naoki
    Fujii, Tsutomu
    Yasuda, Ichiro
    [J]. IN VIVO, 2021, 35 (01): : 475 - 482
  • [3] Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab
    Suematsu, Hideaki
    Kano, Kazuki
    Yamada, Takanobu
    Hashimoto, Itaru
    Watanabe, Hayato
    Takahashi, Kosuke
    Watanabe, Mamoru
    Hayashi, Kei
    Kaneta, Yoshihiro
    Furuta, Mitsuhiro
    Inokuchi, Yasuhiro
    Machida, Nozomu
    Aoyama, Toru
    Tamagawa, Hiroshi
    Yukawa, Norio
    Rino, Yasushi
    Masuda, Munetaka
    Ogata, Takashi
    Oshima, Takashi
    [J]. ANTICANCER RESEARCH, 2022, 42 (03) : 1535 - 1540
  • [4] Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
    Kono, Yoshiyasu
    Choda, Yasuhiro
    Nakagawa, Masahiro
    Miyahara, Koji
    Ishida, Michihiro
    Kubota, Tetsushi
    Seo, Keiji
    Hirata, Tetsu
    Obayashi, Yuka
    Gotoda, Tatsuhiro
    Moritou, Yuki
    Okikawa, Yoshiko
    Iwamoto, Yasuo
    Okada, Hiroyuki
    [J]. TARGETED ONCOLOGY, 2021, 16 (02) : 237 - 248
  • [5] Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
    Yoshiyasu Kono
    Yasuhiro Choda
    Masahiro Nakagawa
    Koji Miyahara
    Michihiro Ishida
    Tetsushi Kubota
    Keiji Seo
    Tetsu Hirata
    Yuka Obayashi
    Tatsuhiro Gotoda
    Yuki Moritou
    Yoshiko Okikawa
    Yasuo Iwamoto
    Hiroyuki Okada
    [J]. Targeted Oncology, 2021, 16 : 237 - 248
  • [6] Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab
    Mashni, Ola K.
    Baba, Dima W.
    Mahmoud, Aseel N.
    Qur'an, Tasnim O.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 577 - 581
  • [7] Characteristics of immune-related adverse events in patients with advanced esophageal cancer treated with nivolumab
    Nakada, Naokatsu
    Ando, Takayuki
    Motoo, Iori
    Kajiura, Shinya
    Fuchino, Mayo
    Sakumura, Miho
    Nanjo, Sohachi
    Mihara, Hiroshi
    Fujinami, Haruka
    Ogawa, Kohei
    Tsukada, Kenichiro
    Nakashima, Koji
    Hosokawa, Ayumu
    Yasuda, Ichiro
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S298 - S298
  • [8] Impact of Immune-related Adverse Events on Nivolumab Efficacy in Patients With Upper Gastrointestinal Cancer
    Booka, Eisuke
    Kikuchi, Hirotoshi
    Haneda, Ryoma
    Soneda, Wataru
    Kawata, Sanshiro
    Murakami, Tomohiro
    Matsumoto, Tomohiro
    Hiramatsu, Yoshihiro
    Takeuchi, Hiroya
    [J]. IN VIVO, 2021, 35 (04): : 2321 - 2326
  • [9] Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy
    Lee, A.
    Girling, B.
    Patel, G.
    Sawhney, P.
    Luong, M.
    Ohana, D.
    Forster, M.
    Lee, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S925 - S926
  • [10] Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy
    Maeda, Takuya
    Yoshino, Koji
    Nagai, Kojiro
    Oaku, Satoe
    Kato, Megumi
    Hiura, Azusa
    Hata, Hiroo
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 115 : 13 - 16
12345